title: [Completion total thyroidectomy in children with differentiated thyroid cancer].
abstract: BACKGROUND
  The optimal surgical treatment of children with differentiated thyroid cancer remains an important point of discussion. Especially the need for completion operation is questioned in young patients. Our objective was to examine the rate of residual neoplastic disease after non radical initial operation.
  
  
  METHODS
  From the 235 children diagnosed with differentiated thyroid cancer, 131 (56%) needed completion operation due to incomplete primary surgery. Completion operation involved thyroid bed, lymph nodes or both respectively in 91 (39%), 13 (6%) and 27 (11%) cases. Risk factors responsible for residual disease were evaluated by means of logistic regression analysis.
  
  
  RESULTS
  Residual disease was detected in 46 (35%) of reoperated children (25% in thyroid bed and 85% in lymph node of lateral neck compartment). Sex and age did not influence the risk of residual disease in thyroid bed or lymph nodes. Papillary type of cancer and multifocality increased risk of residual disease in thyroid bed respectively by the factor of 15 (95% CI: 2-125) and 2.3 (95% CI: 1.2-4.4). Infiltration of thyroid capsule did not correlate with the risk of residual disease. Lymph node metastases in primary operation increased risk of residual disease by the factor of 16 (95% CI: 1.2-245). Histopathology, multifocality of primary tumour or infiltration of lymph node capsule did not influence the risk of residual disease in lymph nodes of lateral neck compartment.
  
  
  CONCLUSIONS
  In children with differentiated thyroid cancer residual disease is diagnosed in about 1/3 of non radically operated cases. This high incidence justifies completion operations. The risk of residual disease is significantly increased in papillary thyroid cancer, multifocal tumours and cases with lymph node metastases.
authors.affiliation: Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice. dhandkiewicz@io.gliwice.pl
authors.forename: Daria
authors.initials: D
authors.lastname: Handkiewicz-Junak
authors.forename: Jan
authors.initials: J
authors.lastname: Włoch
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Czarniecka
authors.forename: Józef
authors.initials: J
authors.lastname: Roskosz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Prokurat
authors.forename: Lech
authors.initials: L
authors.lastname: Pomorski
authors.forename: Jolanta
authors.initials: J
authors.lastname: Krajewska
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Kropińska
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Kukulska
authors.forename: Barbara
authors.initials: B
authors.lastname: Jarzab
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000473:pathology / Q000601:surgery*; D000293:Adolescent; D002291:Carcinoma, Papillary / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D002648:Child; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000473:pathology / Q000601:surgery*; D012086:Reoperation; D013964:Thyroid Neoplasms / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy; D016896:Treatment Outcome